Abstract
There is an urgent need to transform basic research discoveries into tools for treatment and prevention of mental illnesses. This article presents an overview of the National Institute of Mental Health (NIMH) programs and resources to address the challenges and opportunities in psychiatric drug development starting at the point of discovery through the early phases of translational research. We summarize NIMH and selected National Institutes of Health (NIH) efforts to stimulate translation of basic and clinical neuroscience findings into novel targets, models, compounds, and strategies for the development of innovative therapeutics for psychiatric disorders. Examples of collaborations and partnerships among NIMH/NIH, academia, and industry are highlighted.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Armburster BN, Li X, Pausch MH, Herlitze S, Roth BL (2007). Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 104: 5163–5168.
Agid Y, Buzsaki G, Diamond DM, Frackowiak R, Giedd J, Girault JA et al (2007). How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 6: 189–201.
Austin CP, Brady LS, Insel TR, Collins FS (2004). NIH molecular libraries initiative. Science 306: 1138–1139.
Bellack AS, Green MF, Cook JA, Fenton W, Harvey PD, Heaton RK et al (2007). Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull 33: 805–822.
Brady LS, Giffin RB, Woodcock J, Cassell GH, Holmes EW (2008). Grand challenges for psychiatric drug discovery: a perspective. Neuropsychopharmacology 33: 2047.
Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC et al (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31: 5–19.
Carpenter WT, Koenig JI (2008). The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 33: 2061–2079.
Carter CS, Barch DM (2007). Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull 33: 1131–1137.
Chong CR, Sullivan Jr DJ (2007). New uses for old drugs. Nature 448: 645–646.
Conn PJ, Roth BL (2008). Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33: 2048–2060.
Dolen G, Bear MF (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol 586: 1503–1508.
Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM et al (2007). Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry 62: 1324–1333.
Gray JA, Roth BL (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33: 1100–1119.
Huang W, Zheng W, Urban DJ, Inglese J, Sidransky E, Austin CP et al (2007). N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease. Bioorg Med Chem Lett 17: 5783–5789.
Hughes B (2008). 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov 7: 107–109.
Huryn DM, Cosford NDP (2008). The molecular libraries screening center network: identifying chemical probes of biological systems. Annu Rep Prog Chem, Sect A: Inorg Chem 42: 401–416.
Insel TR (2007). From animal models to model animals. Biol Psychiatry 62: 1337–1339.
Insel TR, Scolnick EM (2006). Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 11: 11–17.
Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM et al (2008). The MATRICS consensus cognitive battery, part 2: co-norming and standardization. Am J Psychiatry 165: 214–220.
Kirkpatrick B, Fenton WS, Carpenter Jr WT, Marder SR (2006). The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32: 214–219.
Lazo JS, Brady LS, Dingledine R (2007). Building a pharmacological lexicon: small molecule discovery in academia. Mol Pharmacol 72: 1–7.
Lewis LM, Sheffler D, Williams R, Bridges TM, Kennedy JP, Brogan JT et al (2008). Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Bioorg Med Chem Lett 18: 885–890.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL (2006). Global Burden of Disease and Risk Factors. Oxford University Press/World Bank: New York.
Mailman RB (2007). GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28: 390–396.
Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE et al (2007). Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 32: 2360–2368.
Marder SR, Fenton W (2004). Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72: 5–9.
Mathew SJ, Manji HK, Charney DS (2008). Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33: 2080–2092.
Moran N (2007). Public sector seeks to bridge ‘valley of death’. Nat Biotechnol 25: 266.
Niswender CM, Johnson KA, Luo Q, Ayala JE, Kim C, Conn PJ et al (2008). A novel assay of Gi/o-linked G protein coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Mol Pharmacol 73: 1213–1224.
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD et al (2008). The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165: 203–213.
Pangalos MN, Schechter LE, Hurko O (2007). Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6: 521–532.
Skoumbourdis AP, Huang R, Southall N, Leister W, Guo V, Cho MH et al (2008). Identification of a potent new chemotype for the selective inhibition of PDE4. Bioorg Med Chem Lett 18: 1297–1303.
Stover EL, Brady L, Marder SR (2007). New paradigms for treatment development. Schizophr Bull 33: 1093–1099.
Sung NS, Crowley Jr WF, Genel M, Salber P, Sandy L, Sherwood LM et al (2003). Central challenges facing the national clinical research enterprise. JAMA 289: 1278–1287.
Titus S, Neumann S, Zheng W, Southall N, Michael S, Klumpp C et al (2008). Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. J Biomol Screen 13: 120–127.
Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H et al (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1–13.
Vitiello B (2007). Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology (Berl) 191: 5–13.
Wang PS, Heinssen R, Oliveri ME, Wagner A, Goodman W (2008). Bridging bench and practice: translational research for schizophrenia and other psychotic disorders. Neuropsychopharmacology Reviews (in press).
Wang Q, Jaaro-Peled H, Sawa A, Brandon NJ (2008). How has DISC1 enabled drug discovery? Mol Cell Neurosci 37: 187–195.
Author information
Authors and Affiliations
Corresponding author
Additional information
DISCLOSURE/CONFLICT OF INTEREST
The authors declare that, except for income received from the NIMH, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Brady, L., Winsky, L., Goodman, W. et al. NIMH Initiatives to Facilitate Collaborations Among Industry, Academia, and Government for the Discovery and Clinical Testing of Novel Models and Drugs for Psychiatric Disorders. Neuropsychopharmacol 34, 229–243 (2009). https://doi.org/10.1038/npp.2008.125
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2008.125
Keywords
This article is cited by
-
Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa
CNS Drugs (2019)
-
Drug development in pediatric psychiatry: current status, future trends
Child and Adolescent Psychiatry and Mental Health (2012)
